HeartRhythm

MAY 7, 2024

Implantable cardioverter defibrillator (ICD) prevents sudden cardiac death (SCD) in patients with ischemic cardiomyopathy (ICM). Catheter ablation has been shown to effectively reduce ventricular tachycardia (VT) recurrence, yet its efficacy in patients without an ICD implantation remains uncertain.

Sudden Cardiac Death 45

Sudden Cardiac Death Tachycardia Cardiomyopathy Ablation 45

HeartRhythm

MARCH 14, 2024

Ventricular tachycardia (VT) is a common consequence of both ischemic and non-ischemic heart diseases, often leading to sudden cardiac death. Enhanced sympathetic nerve activity has been implicated in the initiation of VT.

Tachycardia 40

Tachycardia Sudden Cardiac Death Ablation Heart Disease 40

HeartRhythm

NOVEMBER 16, 2024

Patients with repaired tetralogy of Fallot are at risk of ventricular tachycardia (VT) and sudden cardiac death. Historically, risk stratification electrophysiologic studies involved programmed ventricular stimulation with VT induction guiding implantable cardioverter-defibrillator (ICD) implantation or VT ablation.

Sudden Cardiac Death 40

Sudden Cardiac Death Tachycardia Ablation Tricuspid 40

HeartRhythm

JUNE 3, 2024

Recent advancements in catheter ablation for structural ventricular tachycardia (VT), such as high-density mapping and cardiac imaging-based detection of target areas, have significantly improved the efficacy of ablation procedures.

Sudden Cardiac Death 40

Sudden Cardiac Death Tachycardia Ablation Defibrillator 40

HeartRhythm

APRIL 30, 2024

Patients with adult congenital heart disease are at risk for ventricular arrhythmias (VAs) or sudden cardiac death.

Sudden Cardiac Death 40

Sudden Cardiac Death Congenital Heart Disease Tachycardia Congenital 40

HeartRhythm

OCTOBER 15, 2023

Sudden cardiac death remains the main killer of adults in industrialized countries and reentrant ventricular arrhythmia (VA) is its main underlying mechanism1.

Sudden Cardiac Death 40

Sudden Cardiac Death Tachycardia Defibrillator Ablation 40

Heart BMJ

JANUARY 10, 2024

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. Emerging evidence suggests that combining flecainide and bisoprolol may be efficacious.

Cardiomyopathy 40

Cardiomyopathy Sudden Cardiac Death Ablation Arrhythmia 40